China's Duality Biotherapeutics tests market appetite with up to $200 million Hong Kong IPO
SYDNEY (Reuters) -Chinese biotech firm Duality Biotherapeutics launched an initial public offering (IPO) of up to HK$1.56 billion ($200.7 million) on Monday in Hong Kong, testing investor appetite ...
TipRanks on MSN16h
Beam Therapeutics presents additional data for BEAM-302 in AATD
Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency, ...